By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Molecular diagnostics firm OpGen has raised a total of $20 million in its Series B financing round, to be used to advance commercialization of its platform for the generation of de novo whole genome restriction maps.
Registering provides access to this and other free content.
Already have an account?Login Now.
In Nature this week: mouse genome functional analysis, more sensitive chromatin immunoprecipitation, and more.
The Center for Data Innovation and HealthITNow argue for re-building of genomic research infrastructure.
A Senate committee has unanimously approved a bill to require articles resulting from federally funded projects to be made publicly available, according to ScienceInsider.
The US is heading toward another budget showdown, Nature News says.